Table 2.
External Beam Radiation Therapy (EBRT) characteristics.
| Treatment type | N° patients |
| EBRT side | |
| Left | 172 (47.6%) |
| Right | 183 (50.7%) |
| Bilateral | 6 (1.7%) |
| Dose schedule: | |
| Conventional fractionation (50Gy/25 fractions) | 3 (0.8%) |
| Moderate hypofractionation (40.05Gy/15 fractions) | 261 (72.3%) |
| Ultra-hypofractionation (26Gy/5 fractions) | 97 (26.9%) |
| Boost schedule: | |
| Without boost | 208 (57.6%) |
| With concomitant boost (48Gy) | 92 (25.5%) |
| With anticipated IORT boost (20Gy in single fraction) | 35 (9.7%) |
| With consecutive boost (16Gy in 8 fractions) | 26 (7.2%) |
| Systemic therapies | |
| Anthracycline-based chemotherapy | 109 (30.1%) |
| Taxane-based chemotherapy | 119 (33%) |
| Anti-HER2 drugs | 33 (0.8%) |
| Endocrine therapy | 260 (72%) |
| No systemic therapy | 45 (12.5%) |
| Presence of tissue expander before EBRT | |
| Yes | 17 (4.7%) |
| No | 344 (95.3%) |
Postoperative breast radiation therapy characteristics were described. Systemic therapies before or concomitant to irradiation and presence of breast implants were evaluated as possible risk factors for skin toxicity.